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1. INTRODUCTION 
Government and private spending in the healthcare sector has grown significantly in the past 
decades and  continues to grow.  
The contribution of the cost of pharmaceuticals to this growth is not negligible, notably due to the 
increased capabilities of medicine and the development of new technologies in the healthcare 
sector. 
Whilst governments are taking steps to control the rising cost of healthcare, the pharmaceutical 
industry is faced with the problem of  products that will lose patent protection over the next few 
years, fuelling the urgent need to improve its ability to innovate. 
Generic manufacturers with their low cost manufacturing operations are already capitalizing on 
these opportunities in the pharmaceutical industries while considerable efforts are in  progress to 
do so in the biopharmaceutical sector.  
On the other hand, issues like globalization and personalized medicine are bound to radically 
change the playing field for companies and will force them to reconsider their strategies and 
question their competitive advantage. 
These factors, among others is putting the industry under pressure to cut development, 
manufacturing and distribution costs by placing increased emphasis on quality and manufacturing 
efficiencies.  
  According to the Center for Drug Evaluation and Research (CDER), the current good 
manufacturing process allows about 10% waste - an error rate that would be unacceptable in many 
other industries.  
Data compiled by PricewaterhouseCoopers (PwC) argues that the pharmaceutical industry often 
runs plants at 15 per cent or less capacity, accepts that between 5 and 10 per cent of production 
will need to be scrapped or reworked, and that quality control takes up more than 20 per cent of 
total production costs1,2. 
Another study revealed that when compared to other manufacturing sectors, internal production 
efficiency in the pharmaceutical industry is not high, with significant batch rejection rates up to 
30% due in part to a lack of true process understanding and inappropriate approach to quality 
control. 
A report presented by Xcellerex during the IFPAC conference in 2005 estimated a total of 
US$3.6B spent on manufacturing out of specification drugs3. 
Effective and efficient  approach to Quality Control and Assurance of pharmaceuticals will go a 
long way to reduce cost due to waste and batch rejection with significant consequences on the 
COGS. 
COGS were estimated to be $145 billion based on the assumption that COGS is equal to 27% sales 
for brand name pharmaceuticals. (The estimate of global pharmaceutical sales in 2005 is $602 
billion according to the IMS Health Prescription drugs Report 2006). 
Today, there is an urgent need for industries to use their existing resources to address the 
fundamental challenges facing it by investing in innovative development and manufacturing 
processes to guarantee their continued existence. 
The aim of this project is to explore the impacts of new approaches to quality control and 
management in the pharmaceutical and biopharmaceutical industries and their impacts on the 
manufacturing costs. 
COGS reduction will have significant impact on the cost of pharmaceutical products and 
contribute to the overall reduction in the rising cost of healthcare and improve drug availability by : 
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1. Directly impacting the market price of pharmaceuticals 
2. Increased availability of funds that could be diverted to  drug research and  development  
  
Future approaches to routine Quality Control and management  of pharmaceuticals will include: 
1. Risk assessment based on comprehensive understanding of the manufacturing process in 
order to identify the points with critical impacts on the quality of the product. 
2. The exploration and implementation of new sensing and control technologies that will 
allow critical product and process variables to be monitored continuously and controlled 
automatically. 
These approaches coupled with others to be discussed in details in chapter five of this study  will 
dramatically reduce the current industries’ wasteful reliance on quality control via end of 
production testing and off-specification rejection. 
 
1.1 OBJECTIVES  
1. Identify the burden of  routine Quality Control of pharmaceutical and biopharmaceutical 
products on COGS. 
 
2. Evaluate the impacts of the current QC approach on COGS. 
 
3.  Evaluate how the implementation of new approaches to Quality Control and management 
could influence the COGS. 
  
1.2 SCOPE  
1. Routine quality control of marketed pharmaceutical and biopharmaceutical products. 
 
2. Validation and stability studies are not included in this study. 
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2. ROLES OF QUALITY CONTROL IN THE 
PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRIES 
Quality Control is a process employed to ensure a certain level of quality in a product or service. 
The concept of quality control has been applied since the middle ages and it has greatly evolved 
during the industrial revolution period and during the two world wars to its modern day concept. 
To a pharmaceutical manufacturer it implies a detailed system of inspection and control covering 
the evaluation, production and distribution of every drug, with the objectives to produce 
medications of superior efficacy and safety and to provide assurance to the physician, the 
pharmacist and the consumer that a given product performs uniformly and in a satisfactory manner 
for the purpose for which it is recommended.4 
The pharmaceutical quality control laboratory serves one of the most important functions in 
pharmaceutical evaluation, production and distribution5. 
 The EU GMP guidelines requires that each holder of a manufacturing authorization should have a 
Quality Control Department which should be independent from other departments, and under the 
authority of a person with appropriate qualifications and experience, who has one or several 
control laboratories at his disposal, in addition adequate resources must be made available to ensure 
that all the Quality Control arrangements are effectively and reliably carried out. 
A significant portion of the FDA’s 21 CFR part 211 pertain to the quality control laboratory, its 
organization, legal responsibilities and product testing.6 
Some of these responsibilities are clearly detailed in the subpart B 211.22 as follows : 
 
 Approve or reject all components, drug product containers, in-process materials, 
packaging material, labeling and drug products. 
 Authority to review production records to assure no errors have occurred, or if have 
occurred, have been fully investigated. 
 Approve/reject drug products made by other company. 
 Must have adequate lab facilities for testing/approval/rejection of components, drug 
product containers, in-process materials, packaging material, labeling and drug 
products. 
  Approve or reject all procedures or specifications affecting drug product. 
 Responsibilities/procedures must be in writing and must be followed. 
 
2.1 PHARMACEUTICAL INDUSTRY 
The earliest drugstores date back to the middle ages.The first known drugstore was opened by 
Arabian pharmacists in Baghdad in 754, and many more soon began operating throughout the 
medieval Islamic world and eventually medieval Europe. By the 19th century, many of the drug 
stores in Europe and North America had eventually developed into larger pharmaceutical 
companies 
The modern pharmaceutical industry traces its origin to two sources: apothecaries that moved into 
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wholesale production of drugs such as morphine, quinine, and strychnine in the middle of the 19th 
century and dye and chemical companies that established research labs and discovered medical 
applications for their products starting in the 1880s.  
Most of today's major pharmaceutical companies were founded in the late 19th and early 20th 
centuries. Key discoveries of the 1920s and 1930s, such as insulin and penicillin became mass-
manufactured and distributed.  
The industry in Europe is one of the world’s biggest producer of pharmaceutical products, second 
only to the US. Between 1970 to 2000, the industry in Europe accounted for more than 30% of the 
worlds production in pharmaceuticals. Between 1986 and 1990 the major European countries in 
pharmaceuticals (Germany, UK, France, Switzerland and Italy)  demonstrated the most dramatic 
production growth rates (a total increase of 45%) ahead of the US and Japan with 19 and 31% 
respectively. During the late 1990s, Europe lost its lead as the world largest producer of 
pharmaceuticals to the US.7 
With an output of Euro121.3 billion in 2000, the US has taken over the top position followed by 
Europe Euro112 billion and Japan Euro62 billion. Data from 2001 indicates that France is the 
largest producer of pharmaceuticals in Europe with approximately 19% of the European 
pharmaceutical output followed by the UK at 15% while Germany and Switzerland accounts for 
14% each.7,8. Today, the seven main European markets represent a marketplace for pharmaceutical 
products worth US$162 billion a year and its expected to grow by US$47 billion over the next five 
years. 
There are now more than 200 major pharmaceutical companies, jointly said to be more profitable 
than almost any other industry, and employing more political lobbyists than any other industry. 
Advances in biotechnology and the human genome project promise even more sophisticated, and 
possibly more individualized medications. 
2.2 BIOPHARMACEUTICAL INDUSTRY 
The discovery of recombinant DNA and monoclonal antibody technologies in the 1970s marked 
the birth of the biopharmaceutical industry. Unlike chemically synthesized small molecule drugs 
that have long dominated  the traditional pharmaceutical industry, biopharmaceuticals are complex 
macromolecules created through the genetic manipulation of living organisms using gene cloning, 
recombinant DNA (gene splicing), or cell fusion technologies. 
The molecular weight usually varies from about 10,000 to 1,000,000 Daltons while their potency 
may depend on their primary, secondary, tertiary and quaternary structure; glycosylation or disulfide 
bridges between chains or conjugation to small molecule. 
 In terms of product type, these may include recombinant proteins, recombinant antigen vaccines 
and vaccines crafted from genetic material such as DNA, therapeutic monoclonal antibodies and 
Oligonucleotides (short sequences of DNA or RNA) such as antisense molecules which interrupt 
the production of disease causing proteins by inhibiting gene function and gene therapy and can 
enhance the production of a missing protein through the addition of a synthetic gene.9,10 
 Biopharmaceuticals are usually administered by subcutaneous, intravenous, or intramuscular 
injection.   
The biopharmaceutical category also often includes drugs derived from plants, fungi or marine 
organisms, but these are more in the realm of traditional medicinal chemistry research based on the 
random screening of natural compounds. 
Biologics is an area that consists of blood derived polyclonal antibodies and clotting factors, 
antibiotics, and classical vaccines based on live or killed viruses, they are frequently classified as 
biopharmaceuticals, but these products predate the emergence of recombinant DNA and 
monoclonal antibodies. Insulin, for example, was originally obtained from porcine or bovine 
pancreas while human growth hormone was extracted from the pituitary glands of cadavers.  
   9 
2.3 POLICY AND  REGULATORY  
Regulation is designed mainly to protect the health and safety of the population. It is aimed at 
ensuring the safety, quality, and efficacy of the pharmaceutical products which are covered under 
the scope of the regulation. 
The major roles of regulatory agencies in the pharmaceutical industries include but not limited to 
the following : 
 Inspection of facilities, process and product in order to ensure patient or consumer safety. 
 Ensure compliance to applicable regulations. 
 Approve product for marketing. 
 License facility or product. 
 Remove product from the market in case of established risks to patients 
 Remove product license(s). 
 Institute serious regulatory actions or sanctions. 
 
Major international regulatory instances that governs the pharmaceutical and Biotechnology 
industries are the US Food and Drug Administration FDA, the European Agency for the 
Evaluation of Medical Products EMEA, the Japanese Ministry of Health Labor and Welfare 
MHLW, the Swiss Agency for Therapeutic Products Swissmedic and the International Conference 
on Harmonization ICH. 
 
2.3.1 The US Food and Drug Administration (FDA) 
Some milestones in the history of the development of  pharmaceutical regulations include the 1937 
requirement to establish drug safety before marketing following cases of deaths from elixir of 
sulphonamide  containing ethylene glycol; this act is still the basis for regulation of pharmaceutical 
products in the US and most developed countries. 
In 1962 the Kefauver-Harris drug amendment for better drug efficacy and safety were passed; 
manufacturers are required to prove to the FDA the effectiveness of their products before 
marketing, consequence of the thalidomide tragedy in which the use of new tranquillizer in 
pregnant women caused severe birth defects11. 
Legislation was enacted to test and approve drugs and to require appropriate labeling. Prescription 
and nonprescription drugs became legally distinguished from one another as the pharmaceutical 
industry matured.  
In 1964, the World Medical Association issued its Declaration of Helsinki, which set standards for 
clinical research and demanded that subjects give their informed consent before enrolling in an 
experiment. It became a requirement for Pharmaceutical companies to prove efficacy in clinical 
trials before marketing drugs. 
2.3.2 The European Medicine Agency (EMEA) 
In Europe, the EMEA was created in 1985 with the following major roles : 
 Provide independent, science-based recommendations on the quality, safety and efficacy of 
medicines, and on more general issues relevant to public and animal health that involve 
medicines.  
 Apply efficient and transparent evaluation procedures to help bring new medicines to the 
market by means of a single, EU-wide marketing authorisation granted by the European 
Commission.  
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 Implement measures for continuously supervising the quality, safety and efficacy of 
authorised medicines to ensure that their benefits outweigh their risks.  
 Provide scientific advice and incentives to stimulate the development and improve the 
availability of innovative new medicines.  
 Recommend safe limits for residues of veterinary medicines used in food-producing 
animals, for the establishment of maximum residue limits by the European Commission  
 Involve representatives of patients, healthcare professionals and other stakeholders in its 
work, to facilitate dialogue on issues of common interest. 
 Publish impartial and comprehensible information about medicines and their use. 
 Develop best practice for medicines evaluation and supervision in Europe, and contributes 
alongside the Member States and the European Commission to the harmonisation of 
regulatory standards at the international level.12 
 
2.3.3 The Japanese Ministry of Work, Labor and Welfare (MHLW) 
The Japanese Ministry of Work, Labor and Welfare MHLW  was established in January 1938 as a 
new ministry to supervise health, social welfare/insurance and labor administration. 
An advisory organ to the Ministry of Health and Welfare; the Central Pharmaceutical Affairs 
Council is composed of experts in the fields of medical science, pharmaceutical science, veterinary 
science and statistical science which deliberates on available basic and clinical studies data and make 
propositions for drug approval to the Minister of health and Welfare who makes the final decisions 
on the approvals of new drugs 
Good Laboratory Practices (GLP) for the implementation of animal testing (against toxicity) 
during non-clinical tests and Good Clinical Practices (GCP) for the implementation of clinical tests 
are set forth. Each test is regulated by GLP and GCP so that it is conducted appropriately13. 
The major roles of the MHLW in the drug regulatory is as follows : 
 Examinations for the Approval of New Drugs 
 Licenses for the Manufacturing (Import and Sales) of Drugs, etc. 
 Ensure compliance with manufacturing quality control methods 
 Examination of the approval of products other than new drugs 
 
2.3.4 The Swiss Agency for Therapeutic Products (Swissmedic) 
The Swiss agency for therapeutic products Swissmedic is a Swiss based regulatory organ established 
in 2002 and responsible  for the control of pharmaceutical products and medical devices in 
Switzerland. 
 It is a public institution whose core activities cover the following :  
 Licensing medicines 
 Granting authorizations to manufacture and distribute wholesale, and inspecting 
facilities 
 Monitoring medicines and medical devices already on the market 
 Controlling the traffic of narcotics 
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 Laboratory testing of medicine quality 
 Drafting laws and standards  
 
It is independent of other regulatory institutions but works in close collaboration with international 
organizations and governments, it has maintained a good working relation with the Council of 
Europe to draft internationally binding quality standards for medicines. It ensures the application 
European Pharmacopoeia in Switzerland and publish the Swiss Pharmacopoeia14. 
 
2.3.5 The International Conference on Harmonization (ICH) 
The International Conference on Harmonization (ICH) is not a regulatory body but an 
organization established with the objective of promoting international harmonization of guidelines 
and requirements for product registration. 
This objective is pursued by bringing together representatives of the Pharmaceutical Industry and 
regulatory bodies from the EU, Japan and the USA to discuss, establish and recommend common 
guidelines. 
The organization was set up in April 1990 and consist of the following parties : 
 Europe : The European Union (EU) and the European Federation of Pharmaceutical 
Industries and Associations (EFPIA). 
 Japan : Ministry of Health, Labor and Welfare (MHLW), and the Japan Pharmaceutical 
Manufacturers Association (JPMA). 
 United States of America : Food and Drug Administration (FDA) and the Pharmaceutical 
Research and Manufacturers of America (PhRMA). 
Additional members include observers from the World Health Organization (WHO), European 
Free Trade Association (EFTA), and Canada. The observers represent non-ICH countries and 
regions. 
Through the steering committee, the ICH make recommendations on ways to achieve 
harmonization in the interpretation and application of technical guidelines and requirements for 
product registration in order to reduce the need to duplicate the testing carried out during the 
research and development of new medicines.  
The ultimate goal is to encourage economical use of human, animal and material resources, and the 
elimination of unnecessary delay in the global development and availability of new medicines whilst 
maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public 
health. 
Since the beginning of the process, more than 50 technical guidelines have been harmonized in the 
field of quality, safety and efficacy of pharmaceutical products15. 
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3. TYPES OF TESTINGS 
Pharmaceutical and Biopharmaceutical products are tested during the production process in order 
to ensure that the intermediate or active pharmaceutical ingredient (API) conforms to its 
specification (in-process controls). 
Active Pharmaceutical Ingredient (API) is generally referred to as any substance or mixture of 
substances to be used in the manufacture of a drug product and that when used in the production 
of a drug, becomes an active ingredient of the drug product 
Tests are also carried out at the end of the production process (release tests) to verify that the final 
product conforms to the specification required by the applicable pharmacopoeia monograph. 
Most release testing focuses on the physicochemical properties, the identity, the potency, the purity 
and microbiological state of the final drug product. 
3.1 MICROBIOLOGICAL PURITY TESTS 
Microbiological purity tests of pharmaceutical and biopharmaceutical products are conducted in 
order to establish that the intermediate and the final drug products does not contain any foreign 
substance or microorganisms from the process or the manufacturing environment  that could 
potentially harm the patient when the product is used under the prescribed conditions.   
 
 Bioburden 
  Sterility 
 Endotoxin 
 Mycoplasma*  
 Virus testing* 
*Mycoplamsa and virus testing are carried out on biopharmaceutical products.  
3.2 PHYSICOCHEMICAL TESTS 
These are series of tests designed to determine and characterize the physical and chemical 
properties of the intermediates substances and the final drug product. 
Results are often compared to specifications established in the pharmacopoeia monographs; most 
of the tests are listed below : 
 
 Identity  
 Purity 
 Potency assay 
 Pharmaceutical tests 
 Sub-visible particle count 
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3.3 CRITICAL TO QUALITY STEPS 
The Microbiological and Physicochemical tests outlined above are usually carried out in the 
following steps of the manufacturing process: 
3.3.1 API starting  materials and Excipients  
API starting materials are raw materials, intermediates or an API used in the production of an API 
and that is incorporated as a significant structural fragment into the structure of the API.8 
As clearly established in the annex 8 of EU GMP, raw material analysis is an essential process in 
any pharmaceutical manufacturing laboratory. 
“The identity of a complete batch of starting materials can normally only be ensured if individual 
samples are taken from all the containers and an identity test performed on each sample. It is 
permissible to sample only a proportion of the containers where a validated procedure has been 
established to ensure that no single container of starting material has been incorrectly labeled”16 
Raw materials testing ensures that the starting materials and components used in pharmaceutical 
products are suitable for their intended use. Conducting raw materials analysis using appropriate 
test methods and successfully meeting the challenges of such testing can prevent costly production 
problems and delays. 
Methods, specifications and guidelines for testing raw materials are usually specified in the major 
compendia notably the United States Pharmacopoeia/NF, European Pharmacopoeia, Japanese 
Pharmacopoeia, and other regional and international regulatory documents. 
A typical manufacturing process for the production of a liquid drug product use as much as 10 
different excipients whose specifications must conform to those described in the monographs of 
European Pharmacopoeia, US Pharmacopoeia, and the British Pharmacopoeia. 
The EU GMP guidelines allow the use of  supplier's Certificate of Analysis in the place of 
performing  tests other than identity test, under the condition that the manufacturer has a system in 
place to evaluate suppliers.  
The identity test could be skipped in the presence of supplier’s Certificate of Analysis for 
hazardous and highly toxic and dangerous raw materials.16,17 
3.3.2 Intermediates 
These are materials produced during steps of the processing of an API that undergoes further 
molecular change or purification before it becomes an API.8 
These tests are established to monitor the progress and control the performance of processing 
steps that cause variability in the quality characteristics of APIs18. In-process controls play a 
specially important role in ensuring the consistency of the quality of intermediates products and 
eventually the conformity of the final product. 
The EU GMP guideline stipulates that In-process controls and their acceptance criteria should be 
defined based on the information gained during the development stage or historical data. 
The acceptance criteria, the type and extent of testing will depend on the nature of the intermediate 
or API being manufactured, the reaction or process step being conducted, and the degree to which 
the process introduces variability in the product’s quality.  
Less stringent in-process controls may be appropriate in early processing steps, whereas tighter 
controls may be appropriate for later processing steps such as isolation or purification19. 
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In-process controls can be performed by qualified production department personnel and the 
process adjusted without prior quality unit’s approval if the adjustments are made within pre-
established limits approved by the quality control department. 
3.3.3 APIs (drug substances) and Final drug product  
Active Pharmaceutical Ingredient or drug substance is any substance or mixture of substances to be 
used in the manufacture of a drug product and that when used in the production of a drug, 
becomes an active ingredient of the drug product. Such substances are intended to furnish 
pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or 
prevention of disease or to affect the structure and function of the body.8 
Each batch of finished active pharmaceutical ingredient must meet established specifications for 
quality, purity, identity, and potency, including, where applicable, specifications for tests and limits 
for residues of solvents and other reactants. 
Drug substances and each lot of finished drug products are also required to be sterile before release 
for manufacturing process or human use respectively. 
Sterility test is carried out according to USP chapter 71 which is harmonized with the equivalent 
chapters in the EP and JP. 
 
3.3.4 Primary and Secondary packaging materials for drug products 
FDA’s Center for Drug Evaluation and Research has issued several guidance documents 
specifically listing appropriate material and container requirements and testing necessary to 
demonstrate drug safety. 
These requirements are laid out in CDER’s Guidance for Industry — Container Closure Systems 
for Packaging Human Drugs and Biologics, May 1999.20 
The secondary components of the packaged drugs are also controlled for the types of packaging 
material, the dimension , inserts, printed materials and pack integrity. 
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4. MANUFACTURING COST AND QUALITY CONTROL  
Cost of goods sold COGS also referred to as materials and production cost includes all expenses 
directly associated with the production of goods or services  a company sells. It includes items such 
as materials, labor and overheads and exclude depreciation, depletion and amortization. 
COGS is subtracted from sales to determine the gross profit on an income statement. The exact 
costs included in the COGS calculation will differ from one type of business to another. 
In the pharmaceutical and biopharmaceutical industries, cost attributed to manufacturing are a 
major part of a company’s total expenses and it includes all costs incurred in producing the goods 
including write-offs from plant, property and equipment, raw materials, inventory, etc.21 
The manufacturing process of a pharmaceutical product include all activities and operations related 
to the receipt of materials, production, packaging, repackaging, labeling, re-labeling, quality control, 
release, storage and distribution.8 
Manufacturing cost account for a substantial part of the total cost structure and according to some 
estimates, the average figure for a manufacturer of brand-name pharmaceuticals is 26%, 
manufacturer of generics could have as high as 52% while the average in the biotech industry is 
14%.21,22 .The higher value as a percentage of sales for generics is most probably a reflection of 
lower expenditure on R&D and sales and marketing in this sector of the industry. 
 
In 2008, COGS is estimated in absolute terms to be as much as US$200 billion for all 
pharmaceutical products, this estimate is based on the assumption that COGS represent 27% of a 
projected total pharmaceutical sales of US$735 billion in 2008.23 
The high COGS of pharmaceuticals is in part a direct consequence of the necessity to comply with 
local, regional and de facto global regulatory guidelines and government legislations for save and 
efficacious medicines and the methods put in place by the manufacturers to deliver the required 
excellence in terms of quality. 
In the current global environment where investments for new and efficient therapies are becoming 
scarce and the prices of available pharmaceuticals are in constant increase, building quality into 
pharmaceutical and biopharmaceutical process and  products could help to increase manufacturing 
efficiency and  reduce manufacturing cost. 
The reduction in the manufacturing cost would either translate to availability of capital for 
investment in R&D or lower the market prices for pharmaceutical products. Recent studies has 
suggested the existence of strong correlations between COGS reduction and increase in R&D 
expenditure, drug prices and public health.24 
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The following pharmaceutical and biopharmaceutical manufacturers were contacted for data on  
COGS and costs attributable to batch failures, reworks, re-processing and re-labeling. 
Table 4.1 :  Manufacturers contacted for COGS data 
NAME    MEANS OF CONTACT   RESPONSE\RESULT 
ACTELION   E-MAIL THROUGH COMPANY  MANUFACTURING ACTIVITIES ARE  
    WEBSITE    OUTSOURCED 
 
DEBIOPHARM LAUSANNE  E-MAIL, TELEPHONE, SITE VISIT MANUFACTURING ACTIVITIES ARE  
        OUTSOURCED 
 
MERCKSERONO AUBONNE  E-MAIL, TELEPHONE, FACE TO  DATA ON COGS, NO DATA ON BATCH  
    FACE DISCUSSION WITH THE SITE  FAILURE OR OTHERS. 
    FINANCE MANAGER  
 
MERCK ETHICALS DARMSTADT E-MAIL    DATA CANNOT BE PROVIDED FOR 
        CONFIDENTIAL REASONS 
         
 
NOVARTIS BASEL   E-MAIL, TELEPHONE  DATA ON COGS, NO DATA ON BATCH 
        FAILURE OR OTHERS 
 
 
NOVARTIS NYON   E-MAIL    DATA CANNOT BE PROVIDED FOR 
        CONFIDENTIAL REASONS 
 
OM PHARMA GENEVA  E-MAIL, TELEPHONE  NO REPLY TILL DATE 
 
BAXTER CORPORATION, US  E-MAIL    NO REPLY TILL DATE 
 
BRISTOL MEYER SQUIBB, IRELAND TELEPHONE DISCUSSION WITH SUCH DATA ARE CONSIDERED  TO BE 
    CONTACT    CONFIDENTIAL 
 
GLAXOWELLCOME, UK  PERSONAL CONTACT  NO DATA COULD BE PROVIDED 
        FOR CONFIDENTIAL REASONS  
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4.1.1 Pharmaceutical manufacturing cost breakdown 
Table 4.1 below show the cost breakdown data for  pharmaceutical production process simulation 
for company A involved in the production of an active pharmaceutical ingredient (API). The 
process is programmed to produce 171kg  of the compound per batch in a 12 step procedure at 
about US$257/kg. 
Labor is its most important component accounting for 35% of the overall cost, it is estimated that 
16 operators are required to run the plant around the clock supported by four QC/QA scientists. 
The facility-dependent cost, which is essentially composed of depreciation and maintenance of the 
plant, is in the second position at 25%, while raw materials accounts for 24%. 
The percent of the production cost attributed to Quality activities (quality control and assurance) is 
5.3%, however the cost of failed batches or out-of specification result detected at the end of 
production would result in considerable waste in terms of raw materials, labor and efforts deployed 
for investigation, rework and re-processing. 
Company B manufacturing activities involve the conversion of the active pharmaceutical ingredient 
into the final drug product. 
Raw material therefore accounts for the most important part of the production process (80%), 
while facility-dependent and labor-related items account respectively for 9 and 8%. 
QC/QA cost contribution to the production process is 3%, no detail could be obtained concerning 
the cost structure and the degree of automation of the manufacturing process. 
The relative importance of continuous monitoring of critical-to-quality parameters during the 
production process cannot be overemphasized. The risk of dependence on end-of-production 
testing or any other approach, other than on-line or at-line monitoring is very high considering the   
cost of the raw materials alone.  
  
Table 4.2 : Cost breakdown for pharmaceutical manufacturing  
 ITEM            COMPANY A%21             COMPANY B %  
FACILITY-DEPENDENT   25.1           9    
RAW MATERIALS    24.2         80 
LABOR-DEPENDENT    35.4                        8 
QC/QA     5.3                       3 
WASTE TREATMENT/DISPOSAL  10.0           0 
TOTAL     100               100  
 
Table 4.3 :  QC Cost breakdown Company A 
ITEM         % 
PERSONNEL               70 
SUPPLIES         22 
MAINTENANCE        6 
EXTERNAL ANALYSIS       1 
TRAINING         1 
TOTAL         100 
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As shown in table 4.2, the burden of the QC cost in the overall manufacturing cost structure 
cannot be considered to be a major cost driver. 
Typical QC Laboratory in a pharmaceutical set-up will present a cost structure similar to the one 
presented in table 4.3. 
Labor or personnel related (wages and all other forms of compensation) cost account for 71% if 
training is included, materials and reagents account for 27%,  while calibration and maintenance of 
equipment account for 6%. 
This cost structure is coherent with what is obtainable in pharmaceutical quality control 
laboratories under the present labor-intensive approach to quality control and management. 
 
4.1.2 Biopharmaceutical manufacturing cost breakdown 
Table 4.4 below showed cost breakdown for  manufacturing site of a biopharmaceutical company 
whose activities covers fermentation/cell culture, recovery and purification in addition to 
formulation, aseptic filling and packaging of freeze-dried and liquid injectable products. 
 
Table 4.4 : Cost breakdown for Biopharmaceutical manufacturing  
ITEM         % 
FACILITY-DEPENDENT       25 
MATERIALS AND OTHERS        29 
LABOR-DEPENDENT        24 
QC/QA         14 
OVERHEADS        8 
TOTAL         100 
      
Table 4.5 :  Manufacturing Cost breakdown 
ITEM    BIOTECH       SYRINGES   FD       PACK 1              PACK 2 
       
FACILITY-DEPENDENT 17          18              40              22  19  
 
MATERIALS AND OTHERS 37           25                          20                34   34 
         
LABOR-DEPENDENT  28           24              19               27  26 
        
QC/QA   10             25             14               10  15  
       
OVERHEADS  8            8                  7                 7  6 
        
TOTAL   100                100              100            100  100 
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Table 4.6 :  QC Cost breakdown for Biotech, FDF syringes and FD 
ITEM         % 
PERSONNEL               72.6 
SUPPLIES         21 
MAINTENANCE        2 
EXTERNAL ANALYSIS       3 
TRAINING         1.4 
TOTAL         100 
 
Table 4.7 : QC test distribution  
COST ITEM        % 
DEVELOPMENT        15 
BIOTECH PRODUCTION       21 
FINAL DOSAGE FORMS FREEZE DRIED      26 
FINAL DOSAGE FORMS SYRINGES      33 
PACKAGING        5 
TOTAL         100 
 
The QC/QA activities accounted for about 14% of the manufacturing cost in the example of the  
biopharmaceutical industry given above as against an upper limit of 5% in the examples of 
pharmaceutical industries studied. This can probably be explained by the fact that the quantity/type 
and cost of tests required to establish compliance to regulatory requirements for biotech products 
is significantly higher compared to pharmaceutical products. 
It was impossible to obtain additional and similar data from other pharmaceutical and 
biopharmaceutical companies contacted, no trend could therefore be established based on the data 
obtained. However, this data appears to be coherent with generally accepted and published figures 
in industry-related literatures. 
 QC/QA cost per see cannot be considered as a major cost driver in the manufacturing of 
pharmaceuticals and biopharmaceuticals apart from the isolated 25% seen in the FDF syringes 
sector, however the impacts of batch failure or out of specification results will be significant, 
considering the high volume and value of these products. 
The QC Laboratory cost breakdown in table 4.6 is similar to the one presented in table 4.3, with 
labor accounting for a significant portion of the cost, with a slight difference in the cost attributed 
to external analysis.  
External analysis are tests carried out by specialized external laboratories on process samples most 
especially during the cell bank characterization and virus testing of cell culture intermediates of 
Biotech process. 
Table 4.7 shows a progressive increase in QC activities (testing) from 21% in the cell culture 
(Biotech) phase to 33% in the final dosage forms phase of the manufacturing process. 
This is also a confirmation of the industries’ traditional reliance on finished product testing to 
assess the quality of their product, a behavior that encourages less scrutiny on minor variations of 
the process on the way to the final product. 
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4.2 BATCH FAILURE / REJECTION/REWORK/RECALLS 
It was impossible to obtain data related to batch failure, rejection or rework rates in the 
pharmaceutical and biopharmaceutical industries, all the companies contacted declined to give 
information concerning the subject. Information related to the subject were considered confidential 
and are thus not released to the public or for academic purposes. 
Based on the rejection rates between 5 to 10% reported in industry-related articles and  literatures 
for the traditional pharmaceutical 25,26  product, a significant loss due to process inefficiency and 
reliance on end-of-process control is and will continue to be a costly venture for the industry under 
the current approach to quality control and quality management. 
Using the reported US$90 billion/year spent on manufacturing, the cost for the industry will be 
between US$ 4.5 billion and US$ 9 billion per year.21,22,23 
It is also interesting to consider that the number of drug recalls has risen sharply in recent years, 
three-quarters of which are attributed to manufacturing defects.  
The top ten reasons for FDA recalls in the fiscal year 2005 presented below confirmed the fact that 
a large proportion of product recalls are connected to manufacturing and quality-related defects.11 
 
Table 4.6 : Top 10 reasons for FDA recalls in the fiscal year 2005 
TYPE       NUMBER    % 
 
CGMP DEVIATIONS      144    40.6 
 
FAILED USP DISSOLUTION TEST REQUIREMENTS   55    15.5 
 
MICROBIAL CONTAMINATION OF NON-STERILE PRODUCTS  30    8.5 
 
LACK OF EFFICACY      25    7.0 
 
LABELLING ERROR      24    6.8 
 
IMPURITIES/DEGRADATIONS     18    5.1 
 
LACK OF ASSURANCE OF STERILITY    17    4.8 
 
LACK OF PRODUCT STABILITY     16    4.5 
 
MISBRANDED      13    3.7 
 
SUBPOTENT      12    3.4 
 
TOTAL       354    100 
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The European Medicine Agency, EMEA also released a statement on batch recalls for quality 
defects covering the same period (2005). 65 product defects were registered out of which 20 (30%) 
were recalled.12 
A summary of recalls and their classification is presented in the table below: 
Table 4.7 : EMEA classification of batch recalls for quality defects 
TYPE OF RECALL      NUMBER   INCIDENCE 
CLASS I: DEFECTS WHICH ARE POTENTIALLY LIFE 
THREATENING OR COULD CAUSE SERIOUS RISK TO HEALTH        2                  10 
 
 
CLASS 2 : DEFECTS WHICH COULD CAUSE ILLNESS OR  
MISTREATMENT BUT ARE NOT CLASS ONE        4        20 
 
 
CLASS 3 : DEFECTS WHICH MAY NOT POSE A SIGNIFICANT 
HAZARD TO HEALTH BUT WHERE A RECALL HAS BEEN INITIATED 
FOR OTHER REASON BUT NOT CLASS 1 OR 2      14        70 
 
The top 10 reasons for the defects and their incidence are summarized in the table below : 
Table 4.8 : Top 10 reasons for 65 product quality defects registered in the EMEA 
centralized procedure in 2005.12 
TYPE      NUMBER          INCIDENCE 
PRODUCT INFORMATION LITERATURE   14    23.1 
DEVIATION FROM MARKET AUTHORIZATION  10    15.4 
ANCILLARY MATERIALS    9    13.8 
OOS      8                 12.3 
GMP INSPECTION FINDINGS    4    6.2 
CORING PROBLEMS     4    6.2 
PARALELL DISTRIBUTION    3    4.6 
CHEMICAL CROSS CONTAMINATION   2    3.1 
DISSOLUTION TEST     2    3.1 
OMCL OOS     2    3.1 
  
Single events were registered each for microbiological contamination, sterility assurance and 
stability testing. The microbiological cross-contamination case in addition to another serious GMP 
inspection finding not mentioned in the report were the 2 cases in class 1 recall category. 
From tables 4.6 and 4.8 above, significant percent of product defects are directly related to quality 
issues, this shows that the current approach to routine quality control and management of 
pharmaceutical and biopharmaceutical products encourage considerable  wastes in terms of 
resources and time and contribute significantly to the operational/manufacturing and compliance 
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costs with direct consequences on the market price and drug availability. 
Manufacturers as a matter of urgency must seek innovative means of implementing the available 
tools for continuous process monitoring in order to obtain the desired increase in efficiency and   
reduction in manufacturing costs. 
An integrated approach that takes into consideration the implementation of long term measures 
rather than quick fixes should be favored and encouraged.  
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5. FUTURE TRENDS IN THE QUALITY CONTROL OF 
PHARMACEUTICALS AND BIOPHARMACEUTICALS  
“Even as it invents futuristic new drugs, its manufacturing techniques lag far behind those of 
potato-chip and laundry-soap makers” commented a journalist in the Wall Street Journal of 
September 2003 concerning the manufacturing and quality control approaches in the 
pharmaceutical industry.  
The current quality control approach in the pharmaceutical and biopharmaceutical industries 
focuses on end product only, it is reactive rather than proactive to compliance and as a result is 
accompanied with a significant rate of rework-recalls-rejects-retesting and redoing which usually 
translates to increased production costs directly impacting the market prices of drugs and drug 
availability.  
The pharmaceutical and biopharmaceutical manufacturers must as question of necessity start to 
consider the implementation of manufacturing approaches that will employ parametric control on a 
real time basis, therefore assuring 100% inspection and compliance with release specifications. 
This will allow the drug industry to dramatically reduce the current wasteful and cost-intensive 
reliance on quality control via end-product testing and out of specification rejection. 
The impact on cost of manufacturing will be considerable and its social benefits will be felt in 
terms of increased drug availability and consumer surplus. 
     The implementation of some of the tools enumerated in this chapter in an integrated way will 
pave the road to a better and efficient routine quality control and management in the 
pharmaceutical and biopharmaceutical manufacturing. 
5.1 RAPID AND REAL TIME TESTING 
Many new technologies are currently available that provide rapid and continuous information on 
physical, chemical, and microbiological characteristics of pharmaceutical and biopharmaceutical raw 
materials and finished products to improve process understanding and to measure, control and/or 
predict product quality and performance in real time.27,28,29 
 
5.1.1 Physico-chemical testing 
An overview of some of technologies available to the pharmaceutical and biopharmaceutical 
manufacturers for physico-chemical testing  are given below : 
Table 5.1 : Physico-chemical testing 
METHOD       DESCRIPTION 
HIGH RESOLUTION ULTRASONIC SPECTROSCOPY       NON-DESTRUCTIVE ANALYTICAL TOOL BASED ON MEASUREMENT 
           OF THE VELOCITY AND ATTENUATION OF ACOUSTICAL WAVES AT 
           HIGH FREQUENCY, ALLOWS FAST AND ON-LINE ANALYSIS OF 
             COMPOSITION, AGGREGATION, GELATION, DISSOLUTION,  
            MICELLE FORMATION, CRYSTALLIZATION ETC. 
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RAMAN SPECTROSCOPY         RAMAN SCATERRING IS  USED TO DIAGONISE THE INTERNAL  
            STRUCTURE OF  MOLECULES AND CRYSTALS. LIGHT OF A  
            KNOWN FREQUENCY AND POLARIZATION IS SCATTERED FROM 
           A SAMPLE, THEN ANALYZED FOR  FREQUENCY AND POLARIZATION 
           IT MEASURES VIBRATIONS IN APPROXIMATELY THE SAME  INFOR- 
           MATION RICH ENERGY RANGE AS MID-IR 
      
 27, 28 & 29 
 
5.1.2 Rapid microbiology methods 
New methods can reduce the time to results significantly from several days to a few hours, thereby 
allowing  manufacturers to detect adverse trends early and make corrections before they endanger 
products or processes.  
The  table below describe some of the rapid microbiology methods currently available: 
Table 5.2 : Rapid microbiology methods 
METHODS      EQUIPMENTS AND MANUFACTURERS 
GROWTH BASED TECHNOLOGY : BIOCHEMICAL AND PHYSIOLO BIOMERIEUX VITEK 2 AND BACTOMETER SYSTEMS 
GICAL PARAMETERS THAT REFLECT THE GROWTH OF MICRO- BIOLOG OMNILOG 
ORGANISMS AFTER FEW HOURS    MILLIPORE’S MILLIFLEX SYSTEM 
       CELSIS ADVANCE LUMIMOMETER 
       PALL’S PALLCHECK MICRO SYSTEM 
 
VIABILITY BASED TECHNOLOGY: VIABILITY STAINS OR  CELL MARKERS CHEMUNEX SCAN RDI SOLID PHASE CYROMETRY 
TO DETECT AND QUANTIFY ORGANISMS WITHOUT NEED FOR GROWTH CHEMUNEX D-COUNT 
       CHEMUNEX BACTIFLOW 
       ADVANCED ANALYTICAL TECH, RBD 3000 
 
ARTIFACT-BASED TECHNOLOGY : BASED ON THE ANALYSIS OF MIDI SHERLOCK MICROBIAL ID SYSTEM 
CELLULAR COMPONENTS OR THE USE OF PROBES THAT ARE WATERS MICROBELYNX SYSTEM  
SPECIFIC FOR MICROBIAL TARGET SITES OF INTEREST  CHARLES RIVER ENDOSAFE PTS SYSTEM 
       CAMBREX PYROSENSE 
 
NUCLEIC ACID BASED TECHNOLOGY : BASED ON PCR DNA   DUPONT QUALICON RIBOPRINTER 
AMPLIFICATION      APPLIED BIOSYSTEM MICROSEQ 
       SEQUENOMS MASSARRAY PLATFORM 
       BACTERIAL BAR CODE DIVERSILAB 
       IBIS PCR MASS SPECTROMETRY TIGER SYSTEM 
         
27, 28 & 29 
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Table 5.3 : Other tools for process quality management 
DESCRIPTION/OBJECTIVES     TOOLS 
PROCESS ANALYTICAL TECHNOLOGY PAT:   MULTIVARIATE DATA AQQUISITION AND ANALYSIS  
ENHANCE PROCESS UNDERSTANDING    PROCESS ANALYZERS AND  ANALYTICAL 
CHEMISTRY  
MONITOR PROCESS PARAMETERS    PROCESS AND ENDPOINT MONITORING \ CONTROL 
ENCOURAGE CONTINUOS  IMPROVEMENT  CONTINOUS IMPROVEMENT AND KNOWLEDGE 
  MANAGEMENT 
  
 
 
ICH PHARMACEUTICAL QUALITY SYSTEM Q10:   SCIENTIFIC KNWOLEDGE MANAGEMENT TOOLS 
FACILITATE INNOVATION     QUALITY RISK MANAGEMENT TOOLS 
ENCOURAGE CONTINOUS IMPROVEMENT 
STRENGHTEN LINK BETWEEN PHARMACEUTICAL 
DEVELOPMENT AND MANUFACTURING 
OBTAIN CONSISTENCY IN PRODUCT QUALITY 
 
 
 
PARAMETRIC RELEASE:     DATA ACQUISITION AND ANALYSIS TOOLS 
ELIMINATION OF SPECIFIC OR ALL TESTS OF    PROCESS ANALYTICAL CHEMISTRY TOOLS 
API OR ISOLATED INTERMEDIATES.    IN-PROCESS MONITORING TOOLS 
 
 
 
LEAN SIX SIGMA:      RIGHT FIRST TIME USED BY PFIZER 
ELIMINATION OF WASTE     JUST-IN-TIME BY BAXTER CORPORATION 
REDUCTION OF PROCESS VARIABILITY    SIX SIGMA STANDARDIZED STATISTICAL TOOLS  
 
 
QC STATISTICAL PROCESS CONTROL:    CONTROL CHARTS 
PROCESS MONITORING     STATISTICAL TOOLS 
IDENTIFICATION OF REAL PROCESS VARIATION 
EARLY DETECTION AND CORRECTION OF PRODUCT- 
RELATED QUALITY ATTRIBUTES         
    
        
3,30,31,32,33,34 & 35 
 
 
 
   26 
6. SUMMARY AND DISCUSSION  
Historically, pharmaceutical companies have relied on a problematic end of production quality-by-
testing approach with a primary objective of meeting regulatory requirements by performing 
excessive quality control. 
In spite of this approach to quality management, there are indications that the QC per see is not a 
major cost driver under the current system as far as the cases examined in chapter four are 
concerned.  
The information obtained from the data is a confirmation of the current situation in the 
pharmaceutical and biopharmaceutical industries, the data is however not statistically valid for the 
establishment of a definite trend. Additional data would be required to establish a statistically 
valuable trend.  
Apart from the estimated burden of QC on manufacturing costs, the financial impact of rejected 
batches due to out of specification results detected at the end of the  production process would be 
considerable. 
The implementation of some or the combinations of the approaches described in chapter five is 
still considerably low, although some industries are now beginning to embrace the application of 
these tools to manage quality in their manufacturing processes. A recent study conducted by 
Millipore Corporation indicated that more than 70% of companies in the market have become 
aware of PAT within the last few years but less than 40% already have a related program. 
While it is possible to obtain information on the gains in efficiency and COGS savings from the 
implementation of these tools, there are however no clear indications if  and in what ways these 
gains are been translated to consumer benefits.  
Vernon et al proposed 2 economic models where they predicted that a 30% reduction in 
manufacturing cost will generate between $1.0 and $12.3 trillion in social value to the United States. 
Based on several assumptions, the proposed benefits  in terms of consumer surplus, R&D 
investment and the social benefits of the accompanying  R&D investments are presented in tables 
6.1, 6.2 and 6.3 respectively.  
 
Table 6.1 : Consumer Surplus Gain From Reduction In Pharmaceutical Manufacturing 
Costs 24 
% REDUCTION COGS % OF SALES   CONSUMER SURPLUS 1 YR   CONSUMER SURPLUS ALL YEAR 
0   27   0    0 
 
10   24.3   $23.2 BILLION  $330.8 BILLION 
 
20   21.6   $47.4 BILLION  $676.7 BILLION 
 
30   18.9   $72.8 BILLION  $1.0 TRILLION 
 
40   16.2   $99.8 BILLION  $1.4 TRILLION 
 
50   13.5   $128.6 BILLION  $1.8 TRILLION  
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Table 6.2 : Effect of efficiency-induced higher profit margins on R&D Investment24 
REDUCTION COGS %      1 TIME INCREASE IN R&D INVST FLOW  ALL YEAR INCREASE IN R&D  
 
0  27  0                   0.0 
 
10  24.3  $1.9 BILLION   $55.2 BILLION 
 
20  21.6  $3.9 BILLION   $110.4 BILLION 
 
30  18.9  $5.8 BILLION   $165.6 BILLION 
 
40  16.2  $7.7 BILLION   $220.7 BILLION 
 
50  13.5  $9.6 BILLION   $275.9 BILLION   
     
 
Table 6.3 : Effect of efficiency-induced higher profit margins on R&D on Public Health in 
the United States 
REDUCTION COGS %        X          Y  
 
0  27   0                   0.0 
 
10  24.3   $41.0 MILLION   $4.1 TRILLION 
 
20  21.6   $82.1 MILLION   $8.2 TRILLION 
 
30  18.9   $123.1 MILLION   $12.3 TRILLION 
 
40  16.2   $164.1 MILLION   $16.4 TRILLION 
 
50  13.5   $205.2 MILLION   $20.5 TRILLION  
      
X : present value life years gained in the United States, Y : present value dollar benefits (life 
year=$100K) 24 
These models suggested that COGS reduction will either lead to gains in consumer surplus or 
increased spending on R&D of pharmaceutical companies which will also be translated to 
consumers’ benefits. 
 In other words, if COGS can be reduced, the pharmaceutical companies will invest those savings 
into discovery of new therapies for unmet medical needs. In fact, Vernon’s economic model 
calculates that the overall gain in consumer surplus is higher in the scenario where the gains are 
invested in R&D compared to when the gains are translated to a decrease in the market price of 
pharmaceuticals as presented in table 6.3. 
A study conducted by IBM also claims that the top 30 pharmaceutical companies can protect up 
toUS$60 billion  of future revenues, accelerate time to peak sales by two years and reduce Cost of 
Goods Sold (COGS) by up to 16% by managing risk and applying scientific and systems-based 
approaches throughout development and manufacturing.3 
In 2003, Pfizer announced a program called Right First Time (RFT) to migrate its manufacturing 
towards a more predictive approach and quality control. The premise behind RFT was to improve 
Pfizer’s scientific understanding of its process steps, identify the critical variables to quality and 
monitor them with the idea of eventually replacing traditional quality assurance methods with real-
time monitoring.  
Baxter Corporation in the United States also uses Lean principles in its North Carolina plant,  the 
just-in-time (JIT) principle used for the manufacturing of intravenous solutions has witnessed a 
74% reduction in the time between production and release. 
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MerckSerono Biopharmaceuticals is currently applying the  Lean Six Sigma and overall equipment 
efficiency OEE methodologies to the major components of its manufacturing process, support 
activities and equipments.  
The 2 processes are in their early stages and results are not yet available to evaluate their impacts on 
the efficiency on the different processes.  
Novartis’ “Toyota of Pharma vision” presented during the Biophorum 2008 conference based on 
Lean Six Sigma methodologies has yielded encouraging results in terms of throughput time and 
rate, production yield, changeover time and the Overall Asset Effectiveness with a direct impact on 
COGS reduction as presented below : 
 
 
Apart from these examples in the pharmaceutical and Biopharmaceutical industries, technology 
application in other industrial sectors like Telecommunication, Petrochemicals, Automobiles, Steel 
and Information Technology has caused a significant price reductions; better technologies and new 
approaches to manufacture and quality management in pharmaceutical and biopharmaceutical 
production will in no doubt improve the manufacturing process , enhance product quality and help 
collapse costs. 
The direct benefits of implementing the approaches described in chapter five in an integrated 
manner will include the following : 
 Reduce production cycle times by using measurements and control 
 Prevent rejects, scrap, and reprocessing 
 Reduce cost of internal failures 
 Improve process performance 
 Improve efficiency and managing variability 
 Improve operator safety and reduce human error 
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 Reduce cost of delayed implementation of improvements 
 Reduce cost of preparing and reviewing post-approval submissions 
 
    Apart from behavioral and cultural modification on the part of manufacturing and QC  
personnel, the most visible barrier to the implementation of the methods and approaches described 
in chapter five of this work is capital resources, but in many cases, the long-term benefits will far 
outweigh the short-term costs. The success of these approaches will depend on how open 
manufacturers are to the idea that spending more today will save more money in the long run. 
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7. CONCLUSION 
The inherent limitations and consequences of testing-to-compliance without adequate scientific 
knowledge of the process, the  product or raw materials has been seen in recent years. In addition 
to contributing to the manufacturing costs of drugs it is also directly responsible for deaths and 
complications in patients, this trend is bound to continue if adequate science-based measures are 
not taken. Most recent examples are diethylene glycol and heparin saga which has caused several 
deaths and provoked life-threatening allergic reactions. 
Some of the analytical advances and quality management approaches discussed in this work  if and 
when implemented will provoke a complete shift from the current status in the  industry and will 
certainly impact the way the pharmaceutical QC Laboratories work in the future. A change in 
philosophy is therefore necessary to bring about the successful implementation of the integrated 
approach to quality management. 
Under the proposed dispensation, the  concept of quality control is more deeper and covers not 
only product testing which will  be done in most cases on a continuous/in line or at line mode, but 
also process optimization through data monitoring, processing and interpretation. This will 
involved the expertise of highly educated, more mechanically oriented personnel capable to support 
tasks performed throughout the process cycle. 
As significant volume of data will be generated and processed, training of personnel on data 
management, advanced computer use and other electronic devices will become a major cost driver. 
It is difficult at this stage to determine precisely to what extent the implementation of the new 
approaches to quality management will influence the cost structure of QC laboratory, but from the 
look of things, spending on  personnel-related items, most especially wages and trainings will be 
impacted as there will be a need to engage the services of personnel whose qualifications are more 
adapted to the new challenge and also to update the expertise of  the current employees through 
specialized trainings. 
As most of the implementation will be categorized as capital projects by most organizations due to 
the important financial investment required, the QC laboratory management and leadership apart 
from their technical expertise must also be up to date in their knowledge of project management 
tools and be comfortable with the use of value added indicators like Net Present Value (NPV), 
Internal rate of Return (IRR) and Return On Investment (ROI). 
Adequate knowledge in strategic planning and management in addition to capacities to lead change 
successfully will also be required of future QC laboratory management.  
In terms of planning and organization of routine activities, close and continuous collaboration with 
the Production, Information Technology (IT) and Technical Service personnel will be one of the 
challenges to overcome in order to ensure the successful implementation of the system. 
Slight reduction in the cost of laboratory reagents and materials like stationeries and office 
equipment will probably be noticed, as more emphasis will be placed on electronic data and online 
batch records. 
 The part of the QC laboratory cost  spent on the maintenance and calibration of equipment will be 
higher compared to what obtains in most laboratory today. 
New categories of cost item such as, IT materials and supplies, accessories for automated systems, 
Software updates for data processing and management systems will emerge. 
These may initially bring about important increase in QC Laboratory expenditures, but the huge 
benefits that will be obtained by the pharmaceutical industry and the public health sectors far 
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outweigh these initial or permanent increase in QC laboratory expenditures.    
Timothy Tyson in the February 2007 edition of the Journal of Pharmaceutical innovation projected 
that the “Factory of the Future” will employ parametric control on a real time basis assuring 100% 
inspection and compliance with release specifications. Patient and prescriber information will be 
downloaded and printed on-line along with all packaging materials. Demand information will be 
communicated real time to the manufacturing planning system to achieve a just in time process and 
reduce inventories. Capacity utilization will exceed 80% on a three shift per day, 7 days/week basis. 
This will certainly cause a drastic reduction in supply outages, significant improvement in quality 
and regulatory compliance and result in a reduction in billions of dollars of inventory and achieve 
Cost of Goods below 15%.  
This would result in a reduction in costs on an annual basis of greater than $30B per year for the 
industry or the equivalent of 30, one billion dollar per year blockbusters. It’s up to us—it’s about 
innovation—it’s about time”. 
     And for the QC laboratory to thrive under the new environment, it will have to start moving 
towards achieving the challenges the modern manufacturing structure will place on it as it performs 
its statutory roles in the delivery of safe and efficacious drugs to the world in a cost efficient 
manner. 
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